Kubota Pharmaceutical Holdings Co., Ltd. (4596.T) has a MoatMap StockRank of 5/100 based on Quality (34/100), Value (23/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL. Kubota Pharmaceutical is a micro-cap biotech with a broken business model and no commercial traction, failing the Terry Smith rule of never buying turnarounds or pre-revenue speculative healthcare. There is no observable demand signal under the Peter Lynch lens.
Kubota Pharmaceutical Holdings Co., Ltd. is a clinical-stage ophthalmic medical device and biotechnology company focused on developing solutions for vision-threatening diseases. The company's pipeline includes wearable devices for myopia control (Kubota Glass) and small-molecule drugs for retinal diseases. Its competitive advantage lies in its proprietary optometric technologies and focus on high-growth, underserved global ophthalmic markets.
| Price | $0.35 |
| Market Cap | $52M |
| Price/Book | 4.34 |
| Return on Equity | -50.5% |
| Return on Invested Capital | -37.1% |
| Debt/Equity | 1.07 |
| Gross Margin | 352.7% |
| Operating Margin | -7825.0% |
| Revenue Growth | -44.8% |
Kubota Pharmaceutical Holdings Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (Japan).